Hepatitis B virus DNA levels according to the Child-Pugh stage in patients with cirrhosis

Background and Aims: To compare hepatitis B virus DNA levels according to Child-Pugh stage in patients who developed cirrhosis due to hepatitis B virus. Materials and Methods: This study was conducted as retrospectively. Patients who were newly diagnosed with cirrhosis due to hepatitis B virus infection were included. hepatitis B virus DNA, albumin, bilirubin, and international normalization rate levels were compared according to the Child-Pugh Scores. Results: A total of 90 patients (60 males, 30 females) with a mean age of 52.22±9.42 years were included in this study. Each group consisted of 30 patients. Hepatitis B virus DNA level was significantly lower in the Group A compared with the Group B and C (p=0.031). A significant difference was observed between the groups in terms of Child-Pugh scores, albumin, bilirubin, and international normalization rate levels (all p=0.0001). Albumin levels were lower and international normalization rate levels were higher in the Group B and C (all p

Sirozlu hastalarda Child-Pugh evresine göre hepatit B virüs DNA seviyeleri

Giriş ve Amaç: Hepatit B virüsü nedeniyle siroz gelişen hastalarda Child-Pugh evresine göre HBV DNA düzeylerini karşılaştırmak. Gereç ve Yöntem: Retrospektif olarak yapılan bu çalışmaya hepatit B enfeksiyonu nedeniyle yeni siroz tanısı alan hastalar dahil edildi. Hepatit B virus DNA, albümin, bilirübin ve uluslararası normalleştirilmiş oran düzeyleri Child-Pugh Skorlarına göre karşılaştırıldı. Bulgular: Çalışmaya ortalama yaşları 52.22±9.42 olan 90 hasta (60 erkek, 30 kadın) dahil edildi. Her grup 30 hastadan oluşuyordu. Hepatit DNA seviyesi, Grup A’da Grup B ve C’ye kıyasla anlamlı derecede düşüktü (p=0.031). Gruplar arasında Child-Pugh skorları, albümin, bilirübin ve uluslararası normalleştirilmiş oran düzeyleri açısından anlamlı fark bulundu (p=0.0001). Grup B ve C’de albümin düzeyleri daha düşüktü ve uluslararası normalleştirilmiş oran düzeyleri daha yüksekti (p

Kaynakça

Kim SE. Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B. Korean J Int Med 2017;32:631-3.

Polish Group of Experts for HBV, Flisiak R, Halota W, et al. Recommendations for the treatment of hepatitis B in 2017. Clin Exp Hepatol 2017;3:35-46.

Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007;11:797-816.

Chen CJ. Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges. Gut. 2018 doi: 10.1136/ gutnl-2017-315407. Epub 2018 Jan 24.

Ringehan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Transac R Soc Lond B Biol Sci. 2017; 372: 20160274. Erratum in: Philos Trans R Soc Lond B Biol Sci 2018;373.

Gür G. Karaciğer Transplantasyonu. In: Özden A, Şahin B, Yılmaz U, Soykan İ. Gastroenteroloji 1. Basım. Türk Gastroenteroloji Vakfı 2002;672-3.

Lu LG, Zeng MD, Mao YM, et al. Relationship between clinical and pathologic findings in patients with chronic liver diseases. World J Gastroenterol 2003;9:2796-800.

Mohamadnejad M, Montazeri G, Fazlollahi A, et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-Virus related liver disease. Am J Gastroenterol 2006;101:2537-45.

Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 1999;6:1160-74.

Halfon P, Bourlière M, Pénaranda G, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepato 2005;11:6.

Schmilovitz-Weiss H, Tovar A, Halpern M, et al. Predictive value of serum globulin levels for the extent of hepatic fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 2006;13:671-7.

Hui AY, Chan HL-Y, Wong VW-S, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005;100:616- 23.

Kaynak Göster